article thumbnail

Sorry, the Inflation Bill won’t lower healthcare costs

World of DTC Marketing

It’s no wonder that voters consistently rank bringing down prescription drug prices and other measures to reduce the cost of care as among Congress’ top priorities. Congress rightly chose to negioate drug prices for Medicare, but prescription drugs are only 10-12% of every healthcare dollar we spend.

article thumbnail

US legislative update: takeaways for European pharma

European Pharmaceutical Review

In the current US Congressional session, Congress has focused heavily on legislation directed at reducing prescription drug prices. 136 (2013), [link] opinions/12pdf/12-416_m5n0.pdf. 1435 (“Affordable Prescriptions for Patients Act of 2021”), [link] gov/bill/117th-congress/senate-bill/1435/text; H.R. Actavis, 570 U.S.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

5 Core Tenets of HCP-focused Point-of-Care Marketing

PM360

Because nearly all prescriptions are now written electronically. The Point of Care Marketing Association (POCMA) is the Go-to Source for POC Education/Advocacy Founded in 2013, POCMA supports the POC channel through education and advocacy. And to do that in today’s digital age, you’ve got to think “EHR.”

article thumbnail

How retailers and “payviders” are disrupting U.S. healthcare in 2024

Clarivate

RxPass offers more than 50 select prescriptions at no additional cost for $5 per month. In classic Amazon style, its pharmacy offers two-day shipping on prescriptions by mail, with same-day delivery available in seven markets, with plans to add a dozen more cities by year end. The post How retailers and “payviders” are disrupting U.S.

Retail 52
article thumbnail

Fixed-dose combination: Considerations for design, formulation, manufacturing and analysis

Pharmaceutical Technology

Understanding both the significant competitive advantages that FDC products can offer, and the difficulties and potential pitfalls associated with development and manufacturing of FDC drugs in oral solid dosage forms is a critical first step for companies exploring this approach. More FDC products flowing into pharma pipelines.